Related Experiment Video
Updated: Jul 21, 2025
Production and Detection of Reactive Oxygen Species ROS in Cancers
Published on: November 21, 2011
ROS in hepatocellular carcinoma: What we know
Lin Xing1, Yuting Tang1, Lu Li2
1Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China; School of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Abstract:
Hepatocellular carcinoma (HCC), which is a primary liver cancer subtype, has a poor prognosis due to its high degree of malignancy. The lack of early diagnosis makes systemic therapy the only hope for HCC patients with advanced disease; however, resistance to drugs is a major obstacle. In recent years, targeted molecular therapy has gained popularity as a potential treatment for HCC. An increase in reactive oxygen species (ROS), which are cancer markers and a potential target for HCC therapy, can both promote and inhibit the disease. At present, many studies have examined targeted regulation of ROS in the treatment of HCC. Here, we reviewed the latest drugs that are still in the experimental stage, including nanocarrier drugs, exosome drugs, antibody drugs, aptamer drugs and polysaccharide drugs, to provide new hope for the clinical treatment of HCC patients.
Insights
Hepatocellular carcinoma (HCC) treatment faces challenges from drug resistance. This review explores novel experimental therapies targeting reactive oxygen species (ROS) for advanced liver cancer.
Area of Science:
- Oncology
- Biomedical Engineering
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer with poor prognosis, often diagnosed at advanced stages.
- Systemic therapy is the main treatment for advanced HCC, but drug resistance is a significant challenge.
- Reactive oxygen species (ROS) play a dual role in cancer, acting as markers and therapeutic targets.
Purpose of the Study:
- To review emerging experimental drugs for hepatocellular carcinoma (HCC) treatment.
- To focus on novel therapies targeting reactive oxygen species (ROS) in HCC.
- To offer insights into new therapeutic avenues for advanced liver cancer.
Main Methods:
- Literature review of experimental drugs for HCC.
- Categorization of drugs based on delivery systems and targeting mechanisms.
- Analysis of the role of reactive oxygen species (ROS) in HCC pathogenesis and treatment.
Main Results:
- Several classes of experimental drugs show promise for HCC therapy.
- Nanocarrier, exosome, antibody, aptamer, and polysaccharide drugs are being investigated.
- Targeted regulation of ROS presents a potential strategy to overcome drug resistance in HCC.
Conclusions:
- Experimental drugs targeting ROS offer new hope for advanced HCC patients.
- Novel drug delivery systems are crucial for effective HCC treatment.
- Further research is needed to translate these experimental therapies into clinical practice.
More Related Videos
05:16Author Spotlight: High-Throughput Measurement of Intracellular ROS Levels in Hepatocellular Lines
Published on: January 19, 2024
14:25Quantification of Reactive Oxygen Species Using 2′,7′-Dichlorofluorescein Diacetate Probe and Flow-Cytometry in Müller Glial Cells
Published on: May 13, 2022
Related Concept Videos
01:24Peroxisomes
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:20Radical Autoxidation
01:29Oxygen Requirements and Growth Patterns